Discussion about this post

User's avatar
Laura Doty's avatar

Thank you.

Expand full comment
Manuel Gomes's avatar

Dear Dr Crystal thank you once again for this update. Regarding the VRBPAC, the link to the Novavax presentation leads to the Moderna one. I think the right link is this:

https://www.fda.gov/media/179143/download

Seems to me that a sensible decision would be to aprove a KP.2 formulation for the mRNA vaccines while, at the same time, allow the Novavax JN.1. The latter appears to induce a broad Th1 protection to the FLiRT subvariants and is an option for whoever prefers a protein vaccine. This might rise communication problems (protein vs. mRNA), but the public understands that the protection spectrum may vary accross different vaccine platforms.

Manuel

Expand full comment
1 more comment...

No posts